

4DMedical clinical trial results presented at top US lung conference

16 May 2022

Highlights

- Investigators from Johns Hopkins and the University of Miami presented findings from their COPD study on Sunday 15 May in San Francisco at the International Conference of the American Thoracic Society.
- The study in 15 people with a spectrum of COPD disease severity demonstrated that 4DMedical's XV Lung Ventilation Analysis Software (XV LVAS™) is capable of assessing regional ventilation defects, which is critical to optimise therapies.
- COPD is a major respiratory disease, being the third major cause of death throughout the world.
- This clinical trial was undertaken at Johns Hopkins, one of the world's leading medical research institutions.
- 4DMedical has another eight active clinical trials in the US and Australia, with a number of these nearing completion.
- Clinical trials form one of the key pillars of the Company's commercialisation strategy, delivering scientific evidence needed to drive clinical use.

Melbourne, Australia, 16 May 2022: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") announces that findings of its chronic obstructive pulmonary disease (COPD) clinical trial undertaken at Johns Hopkins University Hospital ("Johns Hopkins") were presented at the International Conference of the American Thoracic Society over the weekend.

The scope of the Johns Hopkins study and its findings

Investigators from Johns Hopkins and the University of Miami presented findings from their COPD study on Sunday 15 May at the International Conference of the American Thoracic Society, held in San Francisco. The researchers involved in the study are leading global experts in COPD.



The study involved 15 patients with a spectrum of COPD disease severity who received XV LVAS™ scans twice over the duration of the study. They also underwent other standard assessments of lung function, including Computed Tomography (CT) scans. Key findings of the study included:

- XV Technology™ derived metrics, specifically Ventilation Heterogeneity and Mean Specific Ventilation, correspond with COPD disease severity;
- XV Technology™ derived measures of regional lung function in COPD subjects showed reproducible results during repetitive examinations;
- Pathophysiological insights were identified and have application in both clinical and research settings; and
- XV LVAS™ scans are capable of assessing regional ventilation defects, which is critical to the optimisation of treatment therapies.

The study further demonstrated that XV Technology™ shows significant promise as a tool to phenotype or classify COPD disease. This means that clinicians and investigators now have access to powerful quantitative imaging biomarkers that can regionally identify functional pathology.

Improved monitoring is a critical unmet need in the treatment of COPD


COPD, which develops gradually over time, can be caused by a range of factors, including smoking, long-term exposure to various forms of pollution, and childhood asthma. The disease includes a number of progressive lung conditions including emphysema, chronic bronchitis and chronic asthma.

According to Lung Foundation Australia, around 1 in 7 Australians aged 40 years and over have some form of COPD and around half of these people do not know they have the condition. The disease represents a significant world-wide health problem, and according to the World Health Organisation (WHO) COPD is the third leading cause of death worldwide. However, if diagnosed early enough (prior to the occurrence of structural changes in the lungs), COPD is a treatable condition.

Other clinical trials are also nearing completion

Clinical trials remain a fundamental pillar of the Company's commercialisation strategy. In addition to driving awareness of 4D Medical's technologies amongst the medical community, clinical trial data provide important evidence for indication-specific use by clinicians.

The Company currently has a further eight clinical trials running at hospitals in the US and Australia, including those at Cleveland Clinic, Duke, Vanderbilt and The Alfred. The following diagram highlights the current status of these studies, with several now nearing completion:



4DMedical CEO & Founder Dr Andreas Fouras, said: “We are thrilled with the clinical trial results from the Johns Hopkins COPD study. The trial shows that XV Technology™ has significant promise as a tool to phenotype or classify COPD disease, which is critical for optimising treatment therapies.

Clinical studies like this are a key pillar of our commercialisation strategy. We are excited that more of these studies are likely to conclude over the coming months, with results expected to be presented at key international conferences and published in medical journals. We are confident they will further validate the effectiveness of our unique medical technology offering and serve to make it easier to communicate with doctors and hospitals interested in our offering.”

–ENDS–

Authorised by the 4DMedical Board of Directors.



Contacts

Corporate

Melanie Leydin
Company Secretary

companysecretary@4dmedical.com

Media

Julia Maguire
+ 61 2 8999 3699

julia@thecapitalnetwork.com.au

About 4DMedical

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company focused on delivering the global gold standard in respiratory diagnostics for all lung disorders, including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique and transformative XV Technology™ accurately and quickly scans lung function as the patient breathes, enabling early diagnosis and the monitoring of changes over time.

Our Software-as-a-Service (SaaS) delivered Ventilation Reports provide information and insights far beyond the capabilities of conventional modalities, showing subtle variations in lung function down to the finest details in specific regions of each lung, and with lower exposure to radiation than traditional methods.

Respiratory diagnostics is a US\$31 billion per annum global industry. 4DMedical is disrupting this sector and is committed to providing better information to doctors and patients about lung function.

Better information means better decisions and better outcomes.

Learn more: <https://4dmedical.com>